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Background: HIV/TB coinfection remains a major challenge even after the initiation of HAART. Little is known
about Mycobacterium tuberculosis (Mtb) specific immune restoration in relation to immunologic and virologic
outcomes after long-term HAART during co-infections with latent and active TB.
Methods: A total of 232 adults, including 59 HIV patients with clinical TB (HIV + TB+), 125 HIV patients without
clinical TB (HIV + TB-), 13 HIV negative active TB patients (HIV-TB+), and 10 HIV negative Tuberculin Skin TST positive
(HIV-TST+), and 25 HIV-TST- individuals were recruited. HAART was initiated in 113 HIV + patients (28 TB + and
85 TB-), and anti-TB treatment for all TB cases. CD4+ T-cell count, HIV RNA load, and IFN-γ responses to ESAT-6/
CFP-10 were measured at baseline, 6 months (M6), 18 months (M18) and 24 months (M24) after HAART initiation.
Results: The majority of HIV + TB- (70%, 81%, 84%) as well as HIV + TB + patients (60%, 77%, 80%) had virologic
success (HIV RNA < 50 copies/ml) by M6, M18 and M24, respectively. HAART also significantly increased CD4+ T-cell
counts at 2 years in HIV + TB + (from 110.3 to 289.9 cells/μl), HIV + TB- patients (197.8 to 332.3 cells/μl), HIV + TST-
(199 to 347 cells/μl) and HIV + TST + individuals (195 to 319 cells/μl). Overall, there was no significant difference in
the percentage of patients that achieved virologic success and in total CD4+ counts increased between HIV
patients with and without TB or LTBI. The Mtb specific IFN-γ response at baseline was significantly lower in HIV + TB
+ (3.6 pg/ml) compared to HIV-TB + patients (34.4 pg/ml) and HIV + TST + (46.3 pg/ml) individuals; and in HIV-TB +
patients compared to HIV-TST + individuals (491.2 pg/ml). By M18 on HAART, the IFN-γ response remained impaired
in HIV + TB + patients (18.1 pg/ml) while it normalized in HIV + TST + individuals (from 46.3 to 414.2 pg/ml).
Conclusions: Our data show that clinical and latent TB infections do not influence virologic and immunologic
outcomes of ART in HIV patients. Despite this, HAART was unable to restore optimal TB responsiveness as measured
by Mtb specific IFN-γ response in HIV/TB patients. Improvement of Mtb-specific immune restoration should be the
focus of future therapeutic strategies.
Keywords: HIV, Tuberculosis, HAART* Correspondence: dkassa2003@gmail.com
1Infectious and non-infectious diseases research directorate, Ethiopian Health
and Nutrition Research Institute (EHNRI), P.O. Box 1242, Addis Ababa,
Ethiopia
2Department of Internal Medicine and Infectious Diseases and Department
of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Full list of author information is available at the end of the article
© 2013 Kassa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kassa et al. AIDS Research and Therapy 2013, 10:18 Page 2 of 12
http://www.aidsrestherapy.com/content/10/1/18Background
Human immunodeficiency virus/Acquired immunodefi-
ciency syndrome (HIV/AIDS) associated morbidity and
mortality has reduced substantially since the introduc-
tion of Highly Active Antiretroviral Therapy (HAART)
in the mid 90’s [1,2]. Access to Antiretroviral Therapy
(ART) in low and middle income countries has been ex-
panded following the launche of “3 by 5” global initiative
[3], though only 54% of those eligible for ART were on
treatment by 2011 [2]. In Ethiopia, where free ART was
started in 2005, >250,000 (~79%) of the adults requiring
ART were actually treated [4].
The primary goal of HAART is to suppress HIV-1
RNA lower than the detection level (LDL) of the assay
within 3 to 6 months on treatment and restore immuno-
logic function, to reduce morbidity and mortality, to re-
duce vertical transmission, and improve quality of life
[5]. However, there are still un-resolved problems in-
cluding early mortality [6], incomplete responses [7],
variations in HAART outcomes [8], lack of universal
consensus to define treatment failures and time to start
ART [9], drug resistance [10] and lost to follow-ups [7].
While HIV RNA testing is the golden standard to
monitor patients on ART [8], due to costs and technical
demands of the HIV RNA test, CD4+ T cell measure-
ments are recommended for resource poor settings [11].
Immunologic parameters, however, have lower performance
to identify virologic failures which could lead to premature
change or to continuous use of failed regimens reviewed
in [12]. This leads to higher morbidity and mortality
rates and more complex resistance in settings where viro-
logic tests are not available [13]. Therefore, accurate diag-
nosis of treatment failure is necessary in settings where
free ART service is accelerating and patient monitoring is
exclusively dependent on clinical and CD4+ T cell mea-
surements like in Ethiopia.
Furthermore, despite that HAART has significantly re-
duced morbidity and mortality in HIV/TB patients [14],
studies showed defects of immune response in HIV/TB
patients on HAART including suboptimal restoration
of CD4+ T cells in number, phenotype and function
[15,16], and incomplete TB specific immune restoration
[17]. Higher TB incidence in individuals on continuous
HAART as compared to the HIV negative local popula-
tion, which could be due to incomplete immune resto-
ration specific to TB, was also reported [18]. However,
data regarding the magnitude of immune restoration
specific to Mtb in relation to CD4+ and virologic re-
sponses to long-term HAART in patients with TB and
LTBI is limited.
Overall, although extensive studies aiming to evaluate
ART outcomes have been performed, the studies are
predominantly from developed countries, and they are
different in study design, ex-/inclusion criteria, ethnicity,ART experience, ARV regimen, duration, and defini-
tions, which makes it difficult to generalize HAART out-
comes in different countries [19]. Especially in Ethiopia,
like in many HIV/TB endemic settings, little data is
available [20,21] regarding HAART outcome in patients
with and without active TB and LTBI.
In summary, these studies strongly support the need
of recent data from well defined longitudinal cohort
studies on HAART, which is crucial to provide answers
and insights to the HAART related challenges and de-
velop and update national ART guidelines [19,22].
The aim of this observational cohort study which com-
prised three clinical groups including HIV + TB+, HIV +
TB-, and HIV-TB + patients, and two control groups in-
cluding HIV-TST+, and HIV-TST- individuals , was to
evaluate the long-term outcome of HAART by compre-
hensively measuring key parameters including mortality,
virologic and immunologic responses, and Mtb specific
immune restoration by measuring IFN-γ production in
response to Early Secretory Antigenic Target-6/Culture
Filtrate Protein-10 (ESAT-6/CFP-10).
Results
Characteristics of the study population at enrolment
Demographic, clinical and laboratory data of the study
populations at baseline are shown in Table 1. A total of
232 participants were included. Thirteen HIV-TB+, 59
HIV + TB+, 125 HIV + TB- (of whom 43 were HIV +
TST+, and 82 HIV + TST-), 10 HIV-TST+, and 25 Con-
trols (HIV-TST-) were enrolled. HIV + TB + patients had
lower numbers of CD4+ T cells (p = 0.003), total Lympho-
cyte count (TLC) (p = 0.001), Hemoglobin (Hgb) (g/dl)
(p = 0.02), Body Mass Index (BMI) (Kg/m2) (p = 0.002),
CD4% (p = 0.006), but higher HIV RNA levels (p = 0.02)
than HIV + TB- patients. There was no significant diffe-
rence in CD4+, TLC, Hgb, BMI, CD4% and HIV RNA
tests between HIV + TST- and HIV + TST + individuals
(data not shown). Of special interest, 10 (6.3%) of the
ART naïve HIV patients had HIV RNA < 50 copies/ml
(LDL) at enrolment. The mean CD4+ T cell count of these
subjects was 476.1 (SD ± 260.7 cells/μl).
At enrolment, more than 50% of the HIV + TB + pa-
tients had advanced diseases stages (anemic, malnou-
rished, WHO stages 3 plus 4, and immunosuppressed)
while only 15-36% of the HIV + TB- patients had these
advanced disease stages. There was also a higher per-
centage of chronic hepatitis B virus coinfection in the
HIV + TB + patients, (19.3%), followed by the HIV + TB-,
(7.2%), and healthy controls (4.2%) (Table 1).
Outcome of HAART
ART initiation, mortality and follow-up status
A total of 113 (61.4%) HIV patients including 28 HIV +
TB + and 85 HIV + TB- [of whom 31 were HIV + TST +
Table 1 Baseline characteristics of the study populations (n = 232)
HIV + TB+ HIV + TB- HIV-TB+ HIV-TST+ HIV-TST
(n = 59) (n = 125) (n = 13) (n = 10) (n = 25)
Demographic data
Age, years 33.1 ± 8.7 33.2 ± 7.3 28.5 ± 9.5 b 26.6 ± 7.4, 24.6 ± 6.6
Female, n (%) 28 (47.5) 83 (66.4) 6 (46.2) 6 (60) 16 (64)
Clinical data
CHBV coinfection, n (%) 11/57 (19.3) 8/112 (7.2) 3 (15) 2 (20) 1 (4)
WHO stage, n (%)
I + II 3/50 (6) 80 (64)
III + IV 47/50 (94) 45 (36) NA NA NA
BMI, kg/m2 18.9 ± 3.1a 21.3 ± 3.5 18.9 ± 2.8 21.4 ± 2.5 21.4 ± 2.0
BMI < 18.50 kg/m2, n (%) 29 (49.2) 18/124 (14.6) 6 (46) 8 (80) 24 (96)
Laboratory data
Hgb, g/dl 12.2 ± 3.7 a 13.2 ± 2.5 13.5 ± 2.5 b 16.4 ±1.8 c 18.0 ± 2.1
Hgb < 12 g/dl (anemic), n (%) 23/43 (53.5) 29/107 (27.1) 2 (23) 0 0
CD4+ count/μl 173.7 ± 180.8 a 279.2 ± 212.4 478.1 ± 253 b 787.3 ± 274 754.8 ± 241
CD4+ category, n (%)
< 100 27 (48.2) 26 (22.2) 1 (1.7) 0 0
100 –200 12 (21.4) 26 (22.2) 6 (10.0) 0 0
> = 201 17 (30.3) 65 (55.6) 53 (88.3) 10 (100) 25 (100)
TLC 1175 ± 754 a 1626 ± 750 1485 ± 895 b 1975 ± 1483 1.668 ± 559
HIV RNA (log10copies/ml) 4.5 ± 0.8 a 4.1 ± 0.9 NA NA NA
HIV RNA category, n (%)
LDL 1 (2.2) 9 (8.0)
<= 100000 14 (30.4) 97 (85.8)
>100000 32 (69.6) 16 (14.2) NA NA NA
Data are means ± standard deviations (SD) unless stated; n (%) Number of patients, CHBV chronic Hepatitis B Virus, defined as the presence of hepatitis surface
antigen (HBsAg) in the plasma, BMI Body mass index, Hgb Hemoglobin, TLC total lymphocyte, HIV RNA plasma viral load, LDL lower than detection limit
(HIV RNA < 50 copies/ml), WHO World Health Organization, NA: not applicable.
a Comparing HIV + TB + and HIV + TB-; P < 0.05.
b Comparing HIV + TB + and HIV-TB+; P < 0.05.
c Comparing HIV-TST + and HIV-TST- ; P < 0.05.
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followed for a median of 23.9 (IQR 22.5-24.4) months.
The majority (78%) of the HIV + TB- patients received
D4T + 3TC +NVP HAART regimens. At ART initia-
tion, HIV + TB + patients had lower mean CD4+ T
cells (p = 0.005), CD4% (p = 0.03), TLC (p = 008), and
BMI (p < 0.0001) than HIV + TB- patients (Table 2).
At 2 years, 18 (9.8%) patients died of which 63%
within the first 24 weeks. The risk factors for early mor-
tality in the HIV patients with and without TB were ad-
vanced disease stages including baseline CD4+ count
<100 cells/μl (OR: 5.7, 95% CI 1.8 – 17.2, p = 0.03),
WHO-stages III plus IV (OR: 4.8 95% CI 1.3-17.5,
p = 0.01), and BMI < 18.5 kg/m2 (OR: 1.2 95% CI 0.37-3.8,
p = 0.77) (data not shown).
Overall, at M6, M18 and M24 of follow-up time, 21/59
(35.6%), 21/51 (41.2%) and 23/41 (56.1) of the HIV +TB + patients; and 27/125 (21.6%), 36/120 (30%) and 43/
115 (37.4%) of the HIV + TB- patients, respectively, were
lost to follow-up (more than 60 days late for a scheduled
date of clinic visit).
Virologic outcomes
We measured virologic outcomes by determining the
HIV RNA level as well as the proportion of patients with
virologic success. In both HIV + TB + and HIV + TB-
patients, the mean HIV RNA level significantly de-
clined after HAART (p < 0.05 and p < 0.001, respectively)
(Figure 1A). There was no significant difference in mean
HIV RNA decline between patients with and without TB
or LTBI (Figure 1A & B).
By M24 on HAART, the majority of the indivi-
duals (>80%) achieved virologic success (HIV RNA < 50
copies/ml). There was no significant difference in the
Table 2 Therapeutic, clinical and immunovirologic characteristic of the study participants at ART initiation (n = 113)
HIV + TB+ HIV + TB- p value
No of patients initiated ART 28 85
Demographic
Female, n (%) 14 (50) 56 (65.7)
Age, years 34.1 ± 8.3 34.4 ± 7.7
Treatment
Mean follow-up days before ART initiation 78.7 37.7
Mean delay in commencing HAART following TB treatment, days 100
HAART regimen at ART initiation, n (%)
D4T/3TC/NVP 4 (15) 66 (78)
D4T/3TC/EVZ 11(41) 2 (2)
AZT/3TC/NVP 7(26) 12 (14)
AZT/3TC/EVZ 5 (16) 4 (5)
Others 1 (1)
Cortimoxzole treatment, n (%) 15 (83.3%) 58 (59.2%)
BMI and Laboratory values at ART initiation
BMI (kg/m2) 18.1 ± 2.5 21.3 ± 3.7 0.0001
CD4+ (cells/μl) 110.3 ± 71.3 197.8 ± 153.2 0.005
CD4% 10.1 ± 5.3 14.6 ± 9.9 0.033
TLC (cells/μl) 1078 ± 512 1521 ± 692 0.007
Hgb (g/dl) 13.4 ± 3.4 13.0 ± 2.5 0.68
HIV RNA (log10copies/ml) 4.3 ± 0.9 4.3 ± 0.9 0.73
Follow-up outcomes
Deaths, n (%) 8/59 (13.6) 10/125 (8.0%)
Data in mean ± standard deviation (SD) unless stated; n number of patients, D4T Stavudine, 3TC lamividine, NVP Nevirapine, EVZ Efavirenz, AZT Zidovudin,
BMI Body mass index, Hgb Hemoglobin, TLC total lymphocyte count; M6, M18 and M24 = 6, 18 and 24 months after HAART initiation.
Figure 1 Changes in HIV RNA level (copies/ml) over time after the start of HAART. HIV RNA was measured at baseline, at ART start and at
six month (M6), M18 and M24 of HAART in HIV patients with TB (HIV + TB+) (continuous line) and without TB (HIV + TB-) (dotted line) (A), and
HIV + TB- patients sub-grouped as those with TST positive (HIV + TST+) (continuous line) and TST negative (HIV + TST-) (dotted line) (B). Values are
shown as mean and standard deviation. n = number of participants per visit.
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individuals with and without TB or LTBI (Figure 2A & B).
Moreover, whereas 28 (85%) of the patients on HAART
maintained HIV RNA < 50 copies/ml at M6, M18 and
M24 (ever suppressed), 5 (15%) never reached HIV RNA
< 50 copies/ml (never suppressed).
At M6, 13 (19%) HIV + TB- patients had virologic
failure (HIV RNA >5000 copies/ml), for which baseline
BMI < 18.5 kg/m2, CD4+ count < 100 cells/μl, and WHO
stages 3 and 4 [OR: 3.8, 2.3, 4.9; p = 0.05, 0.32, 0.02, re-
spectively] were risk factors. Other factors like sex (OR:
0.51) age (OR: 0.41), Hgb (OR: 0.19), and HIV RNA
(OR: 0.89) were not associated with the risk of virologic
failures (Table 3).
Immunologic responses
Quantitative restoration of CD4+ cells is one of the prin-
cipal evidences for immune recovery during HAART.
There was a significant increase in CD4+ T cell count at
M6, M18 and M24 of HAART in both the HIV + TB-
(P < 0.001 for all) as well as the HIV + TB + patients
(p = 0.02, 0.001, 0.001, respectively); and in the HIV +
TST + (p = 0.03, 003, 0.04, respectively) as well as in the
HIV + TST- (P < 0.001 for all) (Figure 3A & B).
There was no significant difference in the total CD4+
T cells reached by M6, M18 and M24 in HIV + TB + vs.
HIV + TB- (p = 0.37, 0.63 and 0.56, respectively) and in
HIV + TST + vs. HIV + TST- (p = 0.77, 0.62, and 0.74, re-
spectively) (Figure 3A & B). Interestingly, although the
study population was small, HIV/TB patients coinfected
with HBV (n = 9) showed the least increase in CD4+ T
cells (Figure 3A).Figure 2 Percentages of patients with virologic success (plasma HIV R
overtime on HAART. HIV RNA was measured at six month (M6), M18 and
and without TB (HIV + TB- (dotted line) (A), and HIV + TB- patients sub-grou
negative (HIV + TST-) (dotted line) (B). Percentage of patients with virologic
of participants per visit.There was an overall increase in CD4+ count over the
two years with an average increase of 6.7 cells/μl per
month in the HIV + TB- patients, and 5.9 cells/μl per
month in the HIV + TB+. CD4+ increase was highest in
the first six months. Despite lower CD4+ T cell count at
ART initiation in HIV +TB + patients (110 CD4+ cell/μl)
than HIV + TB- patients (198 CD4+ cell/μl) (p = 0.001),
there was no significant difference in the net increase of
CD4+ T cells per month as well as in the total CD4+ cells
achieved at each time point between the patients with and
without TB.
Overall, at two years on HAART, the total CD4+ cells
in all clinical groups was still lower by more than two
fold compared to healthy controls (HIV-TST-) (771 CD4+
cells/μl) (Figure 3A and B). Moreover, the proportion of
patients that attained the critical CD4+ count of ≥ 200
cells/μl by two years on ART was 19 (68%) for HIV +TB-,
and 8 (73%) for the HIV + TB+. Six (21%) of the HIV +
TB- but none of the HIV + TB + patients had CD4+
count >500 cells/μl (super responders).
At M6, M18 and M24 of HAART, 45%, 30%, 42% of
the HIV + TB- and 54%, 43%, and 30% of the HIV +TB +
patients, respectively, were diagnosed with immunologic
failure (an increase of less than 50 cells/ μl by M6, and less
than 100 cells/ μl by M18 and M24 of HAART). The risk
factors for immunologic failure at M6 of HAART for
the HIV + TB- patients were WHO stages 3 + 4 [OR:
4.3, p = 0.01], and CD4+ < 100 cells/μl) [OR: 5.6, p = 0.008]
at baseline (Table 3).
As shown in Figure 4, for the HIV +TB- patients on
ART, the CD4+ increase was steeper in women, in patients
with older age, patients with baseline HIV RNA < 10000NA < 50 copies/ml) with 95% confidence interval (95% CI)
M24 of treatment in HIV patients with TB (HIV + TB+) (continuous line)
ped as those with TST positive (HIV + TST+) (continuous line) and TST
success per follow up visit are shown on the line graphs; n = number
Table 3 Logistic regression analysis showing odds ratio for factors associated with the risk of immunologic and
virologic failures of the HIV patients with no TB (HIV + TB-) at six months of ART
Risk of immunologic failure
(an increase of CD4+ < 50 cells/μl)
at 6 months (n = 56)
Risk of virologic failure
(HIV RNA > 5000 cells/μl)
at 6 months (n = 69)
OR 95% CI P value OR 95% CI P value
Sex
Male 1 1
Female 0.62 1.0-1.9 0.40 0.51 0.12-2.1 0.93
Age (years)
36-60 1 1
16–35 0.65 0.21-2.0 0.44 0.41 0.10- 1.7 0.21
BMI
<18.50 1 1
> = 18.50 0.90 0.25- 3.29 0.87 3.75 1.0-14.4 0.05
Hgb
< 12 1 1
> = 12 0.38 0.08-1.7 0.21 0.19 0.02-1.6 0.13
CD4+ count/μl
> = 100 1 1
<100 5.6 1.6-20.1 0.008 2.3 0.45- 11.2 0.32
> = 200 1 1
>200 0.22 0.07-0.73 0.01 0.89 0.24-3.2 0.85
HIV RNA copies/ml
> = 100000 1 1
<100000 1.2 0.3- 5.3 0.82 0.38 0.04- 3.3 0.4
WHO stages
I + II 1 1
III + IV 4.3 1.4-13.4 0.01 4.9 1.2-19.9 0.02
TB coinfection
No 1 1
Yes 1.4 0.4-1.8 0.5 0.23 0.03-1.9 0.17
OR Odds ratio, 95% CI 95% confidence Interval; n = total number of participants who have CD4+ count and plasma HIV RNA measurement at 6 month of HAART.
Kassa et al. AIDS Research and Therapy 2013, 10:18 Page 6 of 12
http://www.aidsrestherapy.com/content/10/1/18copies/ml, and CD4+ count > 200 cells/μl with the diffe-
rence becoming larger over time. More interestingly, the
total CD4+ T cell count achieved in the HIV + TB- pa-
tients started ART at CD4+ > 200, was two fold higher
than those started ART at < 200 cells/μl (495.0 vs. 243.2
cells/μl, respectively, (P = 0.007). This indicated that ad-
vanced pre-treatment immunodeficiency is the most im-
portant factor for diminished restoration of CD4 cell
counts after HAART.
Mtb antigen specific IFN-γ response before and after HAART
Although quantitative measurement of CD4+ counts
and HIV RNA level provides a general insight in im-
mune recovery, measuring qualitative restoration of TB
specific immune responses will provide insight whether
antigen specific immune responses are also restored.Therefore, we measured Mtb antigen (ESAT-6/CFP-10)
specific IFN-γ responses during HAART (Figure 5). Com-
pared to IFN-γ response in LTBI individuals (HIV-TST+)
(491.2 pg/ml) at baseline, there was significantly lower
IFN-γ production in HIV +TB + (3.6 pg/ml) (p = 0.004),
in HIV-TB + (34.4 pg/ml) (p = 0.004), and in HIV + TST +
(46.3 pg/ml) patients (p = 0.002). Moreover, IFN-γ pro-
duction at baseline was significantly lower in HIV +
TB + compared to HIV-TB + (p = 0.02) and HIV + TST +
(p = 0.04) patients, and in HIV +TST + compared to HIV-
TB + (p = 0.004).
In the HIV + TST + individuals, following initiation of
HAART, although the level of IFN-γ did not change
by M6 (44.3 pg/ml), it increased sharply after that
and normalized by M18 of treatment (414.2 pg/ml)
(p = 0.007) and reached similar level as HIV-TST +
Figure 3 Mean CD4+ count increase (cells/μl) with 95% Confidence interval (95% CI) over time after the start of HAART. CD4+ T cell
count was measured at ART start, six month (M6), M18, and M24 of HAART in HIV patients with TB (HIV + TB+) (continuous line), with no TB
(HIV + TB-) (dotted line), and HIV patients with TB and HBV (HIV + TB + HBV) (dash line) (A), and HIV + TB- patients sub-grouped as those with TST
positive (HIV + TST+) (continuous line) and those TST negative (HIV + TST-) (dash line) (B). Number of CD4+ T cell counts per follow-up visit are
shown on the line graphs; n = number of participants per visit.
Kassa et al. AIDS Research and Therapy 2013, 10:18 Page 7 of 12
http://www.aidsrestherapy.com/content/10/1/18individuals (491.2 pg/ml) (p > 0.05). In contrast, there
was no significant increase in Mtb specific immunity
for the HIV patients with TB (HIV + TB+) on TB treat-
ment and on HAART by M6 (31.7 pg/ml) as well as by
M18 (18.1 pg/ml) of treatment. For the HIV negative
TB patients (HIV-TB+) on TB treatment, mean IFN-γFigure 4 Mean CD4+ count increase (cells/μl) over time after the star
the baseline category of (A) Age, (B) HIV RNA (copies/ml), (C) Sex, andproduction significantly increased by M6 (181 pg/ml)
(p = 0.005)
To see whether the poor Mtb-specific recovery is due
to lower CD4 recovery, we correlated the increase in
CD4+ cell count in the HIV +TB + patients after HAART
with IFN-γ production upon stimulation with ESAT-6/t of HAART in HIV patients with no TB (HIV + TB-) according to
(D) CD4+ count (cells/μl).
Figure 5 Restoration of Mtb specific IFN-γ (pg/ml) response overtime after the start of HAART and TB treatment. Level of IFN-γ (pg/ml)
was measured at baseline (M0), and at six (M6) and M18 of treatment in 7th day culture supernatants of whole blood stimulated with Mtb
specific (ESAT-6/CFP-10) antigen. HIV + TB+: HIV patients with TB (continuous line); HIV-TB: HIV negative TB patients (long-dash line); HIV + TST+:
HIV positive tuberculin skin test (TST) positive patients (dot line); HIV-TST+: HIV negative TST positive individuals (square dot); and Controls
(HIV-TST-) (circle dot). Mean of IFN-γ (pg/ml) with standard deviation per follow-up visit are shown on the line graph; n = number of participants
per visit shown on the legend.
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correlation between CD4+ T cell count recovery and IFN-
γ production was found (r = 0.19, p = 0.40, n = 22). In con-
trast, however, there was a strong positive correlation
between the recovery of CD4+ cells and IFN-γ produc-
tion in the HIV negative active TB patients (HIV-TB+)
following TB treatment for six months (r = 0.71, p = 0.0007,
n = 19) (Figure 6).
Discussions
In this study, we determined the long-term outcome of
HAART in HIV patients with and without TB and LTBI
by comprehensively measuring HIV RNA suppression,
CD4+ T-cell recovery, and immune reconstitution spe-
cific to Mtb.Figure 6 Spearman correlation between IFN-γ production and absolu
treatment. (A) HIV positive patients with active TB (HIV + TB+) at 6th and 1
patients (HIV-TB+) at six months of TB treatment. IFN-γ secretion was meas
Mtb specific antigen (ESAT-6/CFP-10). r = correlation coefficient.The goal of ART is to suppress HIV-1 RNA below the
detection limit of the assay within 12–24 weeks [5], or
to less than 0 · 5-0 · 75 log copies/ml by 4 weeks [23]. In
this study, 84% of the non-TB patients on HAART had
HIV RNA <50 copies/ml at 24 months on ART. This is
comparable to most studies from Africa [24,25], Europe
[15,26], and United States [27].
Nevertheless, 19% of the non-TB patients in this study
were virologic failures (HIV RNA > 5000 copies/ml) at
6 months of ART. Reports from Cameroon [28] and
Brazil [29] also showed virologic failure (HIV RNA > 400
copies/ml) in 13% and 28% of patients at 6 months on
ART. As reported by Tuboi SH et al. [29], malnutrition
and advanced WHO stages were risk factors for viro-
logic failure in this study, which strongly indicate thete CD4+ count recovery after the start of HAART and TB
8th months of HAART and TB treatment, and (B) HIV negative TB
ured in 7th day culture supernatants of whole blood stimulated with
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initiation of HAART for better treatment outcome.
Interestingly, comparable to other reports [15,30], also
80% of the HIV patients with TB in this study had HIV
RNA < 50 copies/ml at 24 months on HAART, which
is similar to viral suppression in patients without TB
(Figures 1 & 2) and has been reported recently in an-
other study [31]. In contrast, others have reported a high
hazard ratio for virologic failure in patients with TB on
ART [32].
Since many patients in Sub-Saharan Africa present to
the health facilities with advanced disease stages and low
CD4 cell counts [24], they may have limited advantage
for CD4+ recovery after ART [17]. However, despite the
overall lower baseline CD4+ count of the healthy Ethio-
pians [33], and the lower CD4+ count at ART start (197
cells/ μl ) in HIV patients without TB in this study, the
increase in CD4+ cells after two years on ART (332
cells/μl) was comparable with a recent report from
Ethiopia [34], and other reports from Africa [24], in low-
income countries (Africa, Latin America and Asia) [35],
and the United States [27,36]. The mean CD4+ increase
by 24 month on ART in this study (6.7 cells/μl/month)
was also comparable to a report from South Africa [37].
However, 45% of the non-TB patients in this study had
immunologic failure (an increase of <50 CD4+ cells/μl)
at 6 months, while 32% failed to restore CD4+ T cell
count to ≥ 200 cells/μl by 2 years on ART, which is simi-
lar to a study from Nigeria [38]. Similar to Lifson et al.
[36], advance WHO stages and lower CD4+ count at
baseline were risk factors for immunologic failure, which
strongly suggests the need for earlier identification of
eligible patients and initiation of HAART.
Furthermore, since more than 50% of the HIV/TB
patients in Sub-Saharan Africa presented to the health
facilities at advanced disease stages and start ART at
CD4+ counts of 100–150 cells/μl [16,24] the benefit of
patients on ART could be limited [28,39]. More than
50% of the HIV/TB patients in our cohort had advanced
disease stage at enrolment and the CD4+ count at ART
initiation was 110 cells/μl (Table 2). Interestingly, how-
ever, we observed no difference in the CD4+ cell increase
over time on HAART in patients with and without TB as
reported by Lawn SD et al. [40] and Dronda F et al. [31].
In contrast, others reported reduced CD4+ recovery after
ART in patients with TB [15,41,42]. Interestingly, although
the study sample was small, we did observe reduced
CD4+ recovery in HIV/TB patients co-infected with HBV
(Figure 3A) as reported by Pe’ rez-Molina JA et al. [43].
Overall, the total CD4+ count achieved by 2 years on
HAART in patients with TB (290 cells/μl ) and without
TB (332 cells/μl) in this study was comparable to findings
from African and other developed countries, although
it was still lower compared to the healthy Ethiopianpopulations (754.8 cells/μl). This poses the question
whether immune function is restored after 2 year of
HAART. Therefore, the Mtb specific immune restoration
after 18 month on HAART was investigated.
It has been estimated that, if HAART is accessible to
all patients with CD4+ < 200 cells/μl and would restore
optimal immune responses specific to Mtb, the cumulative
incidence of TB would decrease by 22% over 20 years [44].
However, if immune restoration to Mtb is incomplete,
there would be a substantial number of patients on
HAART which are continuously at high risk for TB. In
this study we measured the level of IFN-γ, a cytokine
which plays a key role in the control of Mtb infection [45]
in response to Mtb specific antigen (ESAT-6/CFP-10) [46].
We observed lower IFN-γ secretion in HIV negative
TB patients compared to LTBI individuals at baseline as
reported by Hanna LE et al. [47]. Coinfection with HIV
severely decreased the secretion of IFN-γ in both groups.
Furthermore, in support to previous reports [41,42,48],
IFN-γ production after 18 month of HAART was not re-
stored in HIV patients with TB while it was normalized
in those with LTBI. Among the possible factors contri-
buting to the impaired IFN-γ response in the HIV/TB
patients are exhaustion of immune system [47] defined
as a reduced proliferation of immune cells and impaired
cytokine production due to infection with HIV [49] and
Mtb [50] , and depletion of Mtb specific CD4+ cells due
to direct infection with HIV [15]. Our observation that
there was no correlation between CD4+ count recovery
after HAART and level of IFN-γ production in the HIV +
TB + patients, unlike to that of HIV-TB + patients where
there was a strong correlation between CD4+ T cell re-
covery and IFN-γ production following TB treatment
(Figure 5), suggests that other factors may play a role in
the impaired functional recovery of Mtb specific immune
responses in the HIV + TB + patients. Among the stra-
tegies proposed to boost immune restoration specific to
TB after HAART are early initiation of HAART and iso-
niazid prophylaxis, and adjunctives such as BCG vacci-
nation or co-administration of IL-2 [48,51].
Overall, addressing the long-term outcome of HAART
by comprehensively measuring the key parameters of
ART responses in a well defined cohort of patients with
and without active TB and LTBI is the major strength of
this study. The study addressed immune responses after
HAART not only by measuring the absolute CD4+ cell
recovery as a proxy for immune restoration but also by
measuring IFN-γ response specific to Mtb. However, the
fact that there is no golden standard definition of LTBI
could be counted as limitations of the study
Conclusions
In this observational cohort study, we showed sustained
outcomes of long-term HAART in HIV patients with
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munologic and virologic data. Advanced pre-ART dis-
ease stages were the risk factors for diminished CD4+
and virologic responses to HAART and high mortality,
which strongly indicated the need of early identification
of eligible patients and early access to care and treat-
ment. Mtb specific immune reconstitution in HIV/TB
patients remained impaired after 18 months on HAART,
which suggested the need of strong prevention, earlier
diagnosis, and treatment of TB, as well as earlier initi-
ation of HAART. Factors contributing to impaired Mtb
specific immune restoration in HIV/TB patients after
HAART need to be investigated in order to develop
intervention methods which could boost the immune
response. In addition, we should do further study on
the immunological mechanisms associated with HIV/
TB coinfection.
Materials and methods
Study populations and settings
This observational cohort study was performed from
April 2007-February 2011 at St Peter Specialized Referral
TB Hospital, Akaki and Kality Health centers in Addis
Ababa, Ethiopia. Adults of both sexes who were naïve to
ART and TB treatment were enrolled after informed and
written consent was sought.
Diagnosis of active tuberculosis (TB) was based on
both clinical and bacteriological evidences. At least two
sputum smears stained by the Ziehil-Neelsen direct me-
thod were required to be microscopy positive for Acid
Fast Bacilli (AFB) [52]. Except for TB patients, Mantoux
Tuberculin Skin Testing (TST) for tuberculin was done
for all participants. A diameter of skin induration
with ≥ 10 mm in HIV un-infected, and ≥ 5 mm in HIV-
infected individuals was graded as TST positive (TST+),
and was considered as a LTBI [52].
The study participants were enrolled in 5 clinical
groups: HIV patients with TB (HIV + TB+), and without
TB (HIV + TB-) [sub-grouped further as Tuberculin Skin
Test (TST) positive (HIV + TST+) and TST negative
HIV + TST-], HIV negative TB cases (HIV-TB+), HIV-
TST+, and controls (HIV-TST-). After enrolment, the
HIV + TB+, HIV + TB-, and HIV-TB + groups were sche-
duled for follow-up (FU) clinic visits at sixth month
(M6), M18 and M24.
At enrolment and during FU visit, each participant
was interviewed using a standard questionnaire and de-
tailed clinical, anthropometric and demographic data
were recorded by a clinician or a nurse. A total of 20 ml
heparinized venous blood was collected and transported
immediately to the National HIV Referral Laboratory
(NHL), at EHNRI. HAART was prescribed for eligible
HIV patients and anti-TB treatment for all the TB cases
free of charge as per the national guidelines. Antibioticprophylaxis was also prescribed by the physician at en-
rolment or during the clinic follow-up visits [52].
Laboratory tests
Laboratory examinations of blood were performed by
automated machines following the manufacturer’s proto-
col. Hematological values were determined using Cell
Dyn (Abbott laboratories, Abott Par IC Jl 60064, USA);
CD4+ T cell counts were determined using Becton
Dickinson (BD) FACSCalibur (Becton Dickinson, San
Jose, USA); and Plasma HIV-1 RNA load was measured
using the NucliSens EasyQ NASBA diagnostic 2007/1
(Organon, Teknika) which has a detection range of
50–3,000,000 copies/ml. The level of IFN-γ (pg/ml) in
the 7th day whole blood culture supernatant stimulated
with Mtb specific antigen (ESAT-6/CFP-10) was measured
by xMAP multiplex technology (Luminex, Austin TX,
USA), using Biosource reagents (Biosource, Camarillo,
USA), and analyzed with the STarStation v2.0 software
(Applied Cytometry Systems, United Kingdom) as de-
scribed previously [53].
Definitions
Based on data from different studies [54,55], the national
[56] and international [11] guidelines, and considering
the small sample size in this study, we choose the fol-
lowing cut-off values to define HAART outcomes. Body
mass index (BMI) (kg/m2) was categorized as malnutri-
tion (BMI <18.50) and normal (18.50 ≥ BMI ≤ 24.99), and
anemia was defined as hemoglobin (Hgb) <12 g/dl [57];
virologic success was defined as achieving a viral suppres-
sion (HIV RNA < 50 copies/ml, or lower than the detec-
tion level (LDL) of the assay) after HAART, and virologic
failure as a single HIV RNA >5000 copies/ml after a
minimum of 6 months on HAART [11]. Immunologic
success was defined as an increase of ≥ 50 CD4+ cells/μl
at M6 and ≥100 cells/μl at M18 and M24 from that at
ART initiation; immunologic failure as a failure to in-
crease ≥ 50 cells/μl at M6, or ≥100 cells/μl at M18 and
M24; and super-responders as patients able to achieve
CD4+ count of >500 cells/μl after 2 years of HAART.
Statistical analysis
Data entered using Microsoft Access (DBse XI) was
double-checked for discrepancies. All data analysis was
done using Intercooled STATA version 11.0 (College
Station, Texas, USA). Descriptive analyses including
counts and frequencies for categorical variables, and
mean (standard deviation, SD) or median (interquartile
range, IQR) for continuous variables were computed.
Results were compared using chi-square test and Fisher’s
exact test for categorical variables and non-parametric
tests (Wilcoxon signed rank test and Mann–Whitney U
test) for continuous variables. Fixed (sex, groups) and
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BMI, Hgb, TLC, co-infections) were included in the lo-
gistic regression analysis to identify risk factors for failed
immunologic and virologic responses to HAART. A
p-value of < 0.05 was considered as statistical significant.
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